

Submitted by: Ellen Yang, PharmD U.S. Medical Affairs Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 Phone: (800) 821-8590 Email: <u>genentechmedinfo-d@gene.com</u> Date of request: March 8, 2019 NCCN Guidelines Panel: Breast Cancer

Dear NCCN Breast Panel,

The Food and Drug Administration (FDA) approved Tecentriq[®] (atezolizumab) in combination with nabpaclitaxel for the treatment of patients with PD-L1-positive (PD-L1+) metastatic triple-negative breast cancer (TNBC) on March 8, 2019.¹

Requests:

- Consider the recent FDA-approval of Tecentriq + nab-paclitaxel in patients with PD-L1+ metastatic TNBC and the publication of Phase III IMpassion 130 study for inclusion into the guidelines.^{1,2}
- In the workup for Recurrent/Stage IV breast cancer on page BINV-18, please include determination of tumor PD-L1 status to ensure appropriate patient selection for treatment with Tecentriq.

Rationale:

The IMpassion 130 study met its co-primary endpoints of progression-free survival (PFS) in the intent-totreat (ITT) and PD-L1+ population in untreated metastatic TNBC for Tecentriq + nab-paclitaxel versus placebo + nab-paclitaxel.² The safety profile was consistent with previously reported safety risks of the individual medicines.

- Additional co-primary endpoints included overall survival (OS) in the ITT and PD-L1+ populations. The first interim OS in the ITT population was not statistically significant; however, a numerical OS benefit was observed for the Tecentriq + nab-paclitaxel arm versus placebo + nab-paclitaxel arm in the PD-L1+ population. No formal testing was conducted for the PD-L1+ population (statistical design details reported in the publication and Supplementary Appendix).²
- A pre-specified exploratory biomarker subgroup analysis of IMpassion130 shows that PD-L1 positivity on tumor infiltrating immune cells is a predictive biomarker for PFS and OS benefit for Tecentriq + nab-paclitaxel in first-line metastatic TNBC patients.^{3,4}

Additional studies have been conducted to evaluate Tecentriq in metastatic TNBC.5,6

FDA Clearance:⁷

- Tecentriq in combination with nab-paclitaxel is FDA-approved for PD-L1+ metastatic triple-negative breast cancer (TNBC). Please refer to the product prescribing information for the full FDA-approved indications and safety information of Tecentriq, available at:
 - o <u>https://www.gene.com/download/pdf/tecentriq_prescribing.pdf</u>

Please note that the FDA-approved dose of Tecentriq in TNBC is different than the dose for non-small cell lung cancer (NSCLC) and urothelial cancer listed in the U.S. Prescribing Information.

- TNBC: 840mg administered intravenously on Day 1 and Day 15 of every 28-day cycle
- NSCLC and urothelial cancer: 1200 mg administered intravenously on Day 1 and Day 21 of every 28-day cycle.

Any references supplied to you are protected under U.S. Copyright Law (Title 17, U.S. Code). No further reproduction is permitted.

Thank you for your consideration and I hope this information is helpful to you. If you have any questions, please contact us at the phone number and email provided above.

Respectfully submitted, Ellen Yang, PharmD

References

- FDA Grants Genentech's Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer [Press Release]. South San Francisco, CA; Genentech, Inc. March 8, 2019. Accessed from: <u>https://www.gene.com/media/press-releases/14782/2019-03-08/fda-grants-genentechs-tecentriqin-combi</u>
- Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. [supplementary appendix appears online]. N Engl J Med. 2018 Nov 29;379:2108-2121. <u>https://www.ncbi.nlm.nih.gov/pubmed/30345906</u>
- Emens LA, Loi S, Rugo HS, et al. IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab + nabpaclitaxel in patients with treatment-naive, locally advanced or metastatic triple-negative breast cancer. Presented at the San Antonio Breast Cancer Symposium in San Antonio, TX; December 4–8, 2018. SABCS Oral Presentation.
- 4. Protocol for IMpassion130: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination with NAB-Paclitaxel for Patients with Previously Untreated Metastatic Triple-Negatice Breast Cancer. January 2015. Available at <u>https://www.nejm.org/doi/suppl/10.1056/NEJMoa1809615/suppl_file/nejmoa1809615_protocol.pdf</u>. Accessed on February 12, 2018.
- Adams S, Diamond JR, Hamilton E, et al. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol. 2018 Oct 19. DOI: 10.1001/jamaoncol.2018.5152. [Epub ahead of print]
- Emens LA, Cruz C, Eder JP, et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 Jan 1;5:74-82. <u>https://www.ncbi.nlm.nih.gov/pubmed/30242306</u>
- 7. Tecentriq[®] [package insert]. Genentech; South San Francisco, CA. 2019.